SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek
Key Highlights
- ➤SCY-247 to be featured in an oral pipeline presentation at IDWeek
- ➤SCY-247 is a phase 2 IV/oral antifungal candidate targeting invasive fungal infections
- ➤BARDA contract provides up to approximately $214 million in non-dilutive funding, milestone-dependent
- ➤SCY-247 has FDA Orphan Drug, QIDP and Fast Track designations
Expert Statements
David Angulo, President and Chief Executive Officer of SCYNEXIS
“SCY-247, a novel phase 2 IV/oral triterpenoid antifungal”
JERSEY CITY, N.J., Oct. 21, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, announces that SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate, will be featured in an oral company pipeline presentation at IDWeek, being held October 21-24, 2026 at the Walter E. Washington Convention Center in Washington, D.C. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi.
Title:SCY-247, a novel phase 2 IV/oral triterpenoid antifungal
Get started
Create a free account to read the full story.